Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KERENDIA vs ALPHADROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.
Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.
To reduce the risk of sustained e GFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes.
Adjunctive therapy for short-term administration in severe allergic reactions,Management of inflammatory and autoimmune conditions,Off-label: Treatment of certain cancers (e.g., multiple myeloma, lymphoid malignancies)
10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.
0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.
The terminal elimination half-life is approximately 2–4 hours in healthy subjects. In patients with renal impairment, the half-life may be prolonged up to 6–8 hours, allowing for once-daily dosing in chronic kidney disease.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily metabolized by CYP3A4 (≈90%) and to a lesser extent by CYP2C8 (≈10%). No active metabolites.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Approximately 80% of the dose is eliminated via feces (primarily as unchanged drug) and ~20% via urine (mostly as metabolites). Renal excretion of unchanged drug is minimal (less than 1%).
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugates (20-25%); biliary/fecal excretion accounts for 5-10%.
Approximately 92% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein.
Highly protein bound (92-95%), primarily to albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution is approximately 50 L (about 0.7 L/kg in a 70 kg adult), indicating moderate tissue distribution, likely into kidney and heart tissues.
0.8-1.2 L/kg; indicates extensive distribution into total body water with some tissue binding.
Oral bioavailability is about 90–95% in healthy subjects, indicating nearly complete absorption after oral administration. Food does not significantly affect absorption.
Oral: 70-80% due to first-pass metabolism; intramuscular: 90-100%.
e GFR 25-59 m L/min/1.73 m²: Initiate 10 mg once daily; continue 10 mg if tolerated. e GFR <25 m L/min: Not recommended.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of dose; GFR <10 m L/min: avoid use due to risk of accumulation.
Child-Pugh B (moderate impairment): 10 mg once daily. Child-Pugh C (severe impairment): Not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established in pediatric patients.
0.01 mg/kg intravenously every 4-6 hours; maximum 0.2 mg/kg/day.
No specific dose adjustment required; monitor renal function closely.
Initiate with 0.25 mg intravenously every 6 hours; titrate cautiously due to increased sensitivity and renal impairment.
No FDA boxed warning.
None
Hyperkalemia: Monitor serum potassium levels; may require dose adjustment or discontinuation.,Hypotension: Risk increased in patients with volume depletion or concomitant antihypertensive therapy.,Acute kidney injury: Monitor renal function; consider temporary discontinuation in setting of significant renal impairment.,Hepatic impairment: Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Increased risk of infections due to immunosuppression,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Exacerbation of diabetes mellitus,Psychiatric disturbances
Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir).,Addison's disease (adrenal insufficiency).,Serum potassium > 5.0 m Eq/L at initiation.
Systemic fungal infections,Hypersensitivity to the drug or any component,Administration of live or live attenuated vaccines
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase finerenone exposure. No other food interactions noted.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Take with food to reduce gastrointestinal irritation. Limit sodium intake to reduce fluid retention; consider potassium-rich foods.
Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiovascular, skeletal) were observed at maternal exposures below the maximum recommended human dose. In rabbits, increased post-implantation loss and decreased fetal weights occurred. There are no adequate human studies. Use is contraindicated in pregnancy. Avoid in women of childbearing potential not using effective contraception.
ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and adrenal suppression. Risk category X.
No data on presence in human milk, effects on breastfed infant, or milk production. Excreted in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy and for 1 week after last dose.
Excreted into breast milk; M/P ratio not reported. Potential for infant adrenal suppression and growth retardation. Breastfeeding not recommended during therapy and for at least 3 months after last dose.
Kerendia is contraindicated in pregnancy. No dose adjustments are provided due to lack of human data; use is not recommended. Pharmacokinetic changes in pregnancy are unknown, but dose modifications are not applicable as therapy should be discontinued if pregnancy occurs.
Avoid use in pregnancy; no established dose adjustments; use lowest effective dose if unavoidable; increased clearance may require dose increase, but teratogenicity risk precludes use.
Monitor serum potassium closely, especially in patients with e GFR <30 m L/min/1.73m² or baseline K+ >5.0 m Eq/L. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). Contraindicated with concomitant mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone). Use caution with moderate CYP3A4 inhibitors (e.g., erythromycin, verapamil) and moderate CYP3A4 inducers (e.g., rifampin, phenytoin). Assess e GFR and serum potassium before initiation and at 1 month after starting or adjusting dose.
Monitor blood glucose closely in diabetic patients; may cause hyperglycemia. Administer with food to reduce GI upset. Taper dose over 1-2 weeks after prolonged use to avoid adrenal insufficiency. Avoid live vaccines during therapy.
Take this medication exactly as prescribed, usually once daily with or without food.,Do not use potassium supplements or salt substitutes containing potassium without consulting your doctor.,Report symptoms of hyperkalemia (e.g., muscle weakness, fatigue, palpitations, numbness) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking KERENDIA (finerenone).,Do not stop taking KERENDIA without talking to your doctor.,Store at room temperature, away from moisture and heat.
Take with food or milk to prevent stomach upset.,Do not stop taking this medication suddenly without consulting your doctor.,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.,Avoid alcohol while on this medication.,Inform all healthcare providers that you are taking Alphadrol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KERENDIA vs ALPHADROL, answered by our medical review team.
KERENDIA is a Mineralocorticoid Receptor Antagonist that works by Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.. ALPHADROL is a Mineralocorticoid that works by Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KERENDIA and ALPHADROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KERENDIA is: 10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.. The standard adult dose of ALPHADROL is: 0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KERENDIA and ALPHADROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KERENDIA is classified as Category C. Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiov. ALPHADROL is classified as Category C. ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.